Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

This trial tests a combination of three treatments — an immune-boosting antibody (anti-CD38), a KRAS cancer vaccine, and an immune checkpoint drug (anti-PD-1) — in people with advanced pancreatic cancer or lung cancer that has stopped responding to standard immunotherapy. **You may be eligible if...** - You are 18 or older - You have advanced non-small cell lung cancer that worsened on PD-1/PD-L1 therapy, OR pancreatic cancer that failed one prior treatment - Your tumor has a KRAS mutation - You are well enough to do light activity (ECOG 0–2) - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You are pregnant, breastfeeding, or not using contraception - You recently had surgery, chemo, or radiation (within the required washout period) - You have uncontrolled heart disease, active infection, or HIV/Hepatitis B/C - You have previously received an anti-CD38 drug (like daratumumab) - You have active autoimmune disease requiring treatment Talk to your doctor to see if this trial is right for you.